3,5-Pyrazolidinedione,4-butyl-1-(4-hydroxyphenyl)-2-phenyl-;OXYPHENYL BUTAZONE;4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione;Oxyphenbutazone;4-Butyl-1-(4-hydroxyphenyl)-2-phenyl-3,5-pyrazolidinedione G 27202;Etrozolidina;Idrobutazina;ossifenbutazone;Oxazolidin;Oxi-Fenibutol;Oxifenylbutazon;Oxiphenbutazone;oxyphenbutazon;p-Oxyphenylbutazone;Tanderil;4-Butyl-1-(4-hydroxyphenyl)-2-phenyl-3,5-pyrazolidinedione;G 27202;NSC 526053;Ro 04-4410;p-Hydroxyphenylbutazone;4-Butyl-2-(p-hydroxyphenyl)-1-phenyl-3,5-pyrazolidinedione;Butapirone;Californit;Crovaril;Flamaril;Floghene;Flogitolo;Flogoril;Frabel;Metabolite I;Neo-Farmadol;Offitril;Oxalid;Oxyphenobutazone;Rapostan;Romaxin;Suganril;Tandacote;Tandearil;Telidal;Tendearil;Visubutina;bm1;Flogal;Iridil;Mysite;Neofen;Reumox;c;Oxyphenylbutazone;BM 1;g27202
Cas No.
129-20-4
分子式
C19H20N2O3
分子量
324.37
包装储存
Powder
-20°C
3 years
In solvent
-80°C
6 months
-20°C
1 month
生物活性
Oxyphenbutazone is a Phenylbutazone (HY-B0230) metabolite, with anti-inflammatory effect. Oxyphenbutazone is an orally active non-selective COX inhibitor. Oxyphenbutazone selectively kills non-replicating Mycobaterium tuberculosis.
性状
Solid
IC50 & Target[1][2]
COX, Bacteria
体外研究(In Vitro)
Oxyphenbutazone enhances the anticancer efficiency of Methotrexate (MTX) (HY-14519) in Hep3B cells.
Oxyphenbutazone (2.5-7.5 μM; 48 hours) co-treatment with (MTX, 0.25-1.0 μM) shows potential cytotoxicity against Hep3B cells.
Oxyphenbutazone exhibits reparative effects in the hepatocytes.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Cytotoxicity Assay
Cell Line:
Hep3B cells
Concentration:
2.5 μM, 5 μM, 7.5 μM
Incubation Time:
48 hours
Result:
Enhanced the cytotoxicity of MTX.
体内研究(In Vivo)
Oxyphenbutazone (70 mg/kg/week; p.o.; in two divided doses; for 13 weeks) exerts potential anticancer activity when co-treatment with MTX (5.0 or 2.5 mg/kg/week; i.p.).
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Wistar strain albino male rats (5-6 weeks; 150-220 g)
Dosage:
70 mg/kg/week (co-treatment with MTX 5.0 or 2.5 mg/kg/week)
Administration:
PO; once a week; in two divided doses; for 13 weeks
Result:
Exerted potential anticancer activity in rats when co-treatment with MTX.